14 January 2021 - What distinguishes an 'outcome' from an 'other matter?"

The outcomes from the November 2020 PBAC meeting include four other matters.  All four relates to submissions for medicines lodged by their respective sponsors:

• Dupilumab (Dupixent) - Sanofi
  
• Galcanezumab (Emgality) - Eli Lilly
  
• Tofacitinib citrate (Xeljanz) - Pfizer
  
• Upadacitinib citrate (Rinvoq) - AbbVie
  

All four submissions were featured in the published agenda for the November 2021 meeting.

Why have the 'outcomes' for these four medicines/submissions been published as 'other matters' rather than as outcomes (i.e. recommendations)?  In the past, outcomes like these have been published as 'outcomes'.  Could it be that the Department wants these outcomes to be less visible?